A vs. BMY: Agilent vs. Bristol-Myers Squibb Stock Comparison

Company Profile

Agilent (A) and Bristol-Myers Squibb (BMY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while BMY is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Agilent (A) at 20.97% and Bristol-Myers Squibb (BMY) at 44.01% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Agilent (A) at 19.53% and Bristol-Myers Squibb (BMY) at 18.47% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Agilent (A) at 25.56% and Bristol-Myers Squibb (BMY) at 33.79% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Agilent (A) at 6.73% and Bristol-Myers Squibb (BMY) at -0.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Agilent (A) reports EPS growth of 3.16%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Agilent (A) at 2.05 and Bristol-Myers Squibb (BMY) at 1.59 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Agilent (A) at 0.56 is near its industry mid-range for debt-to-equity ratio, while Bristol-Myers Squibb (BMY) at 1.91 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Both Agilent (A) at 0.59% and Bristol-Myers Squibb (BMY) at 3.99% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Agilent (A) at 19.98% and Bristol-Myers Squibb (BMY) at 55.88% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Both Agilent (A) at 34.47 and Bristol-Myers Squibb (BMY) at 13.78 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Agilent (A) at 6.68 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

Bristol-Myers Squibb (BMY) at 5.43 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.

Valuation Metrics